{"id":"https://openalex.org/W2553714461","doi":null,"title":"Pharmacology of \"atypicality\" of antipsychotic drugs: status and perspectives","display_name":"Pharmacology of \"atypicality\" of antipsychotic drugs: status and perspectives","alternate_titles":[],"publication_year":2010,"publication_date":"2010-01-01","ids":{"openalex":"https://openalex.org/W2553714461","mag":"2553714461"},"language":"en","primary_location":{"id":"mag:2553714461","doi":null,"is_oa":false,"landing_page_url":"http://www.archivespp.pl/uploads/images/2010_12_4/NewmanTancredi5__archives%204_10.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"parent_works":[],"lineage":["https://openalex.org/W2553714461"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5045801598","display_name":"Adrian Newman\u2010Tancredi","orcid":"https://orcid.org/0000-0002-2923-5714","observed_orcids":["https://orcid.org/0000-0002-2923-5714"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Adrian Newman\u2010Tancredi","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2923-5714","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5083060102","display_name":"Mark S. Kleven","orcid":"https://orcid.org/0000-0001-5413-4475","observed_orcids":["https://orcid.org/0000-0001-5413-4475"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Mark S. Kleven","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-5413-4475","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.3441,"has_fulltext":false,"cited_by_count":9,"citation_normalized_percentile":{"value":0.60695048,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":95},"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.002099999925121665,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/atypical-antipsychotics","display_name":"atypical antipsychotics","score":0.9990000128746033},{"id":"https://openalex.org/keywords/5-ht1a-receptor","display_name":"5-HT1A receptor","score":0.8100000023841858},{"id":"https://openalex.org/keywords/dopamine-d2-receptor","display_name":"dopamine D2 receptor","score":0.9229999780654907},{"id":"https://openalex.org/keywords/partial-agonists","display_name":"partial agonists","score":0.5540000200271606},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.5580000281333923},{"id":"https://openalex.org/keywords/negative-symptoms","display_name":"negative symptoms","score":0.8629999756813049},{"id":"https://openalex.org/keywords/cognitive-impairment","display_name":"cognitive impairment","score":0.9940000176429749},{"id":"https://openalex.org/keywords/extrapyramidal-symptoms","display_name":"extrapyramidal symptoms","score":0.9010000228881836},{"id":"https://openalex.org/keywords/metabolic-side-effects","display_name":"metabolic side effects","score":0.7870000004768372},{"id":"https://openalex.org/keywords/aripiprazole","display_name":"aripiprazole","score":0.8989999890327454},{"id":"https://openalex.org/keywords/perospirone","display_name":"perospirone","score":0.8370000123977661},{"id":"https://openalex.org/keywords/bifeprunox","display_name":"bifeprunox","score":0.9179999828338623},{"id":"https://openalex.org/keywords/lurasidone","display_name":"lurasidone","score":0.9990000128746033},{"id":"https://openalex.org/keywords/cariprazine","display_name":"cariprazine","score":0.9639999866485596},{"id":"https://openalex.org/keywords/dopamine-serotonin-interaction","display_name":"serotonin-dopamine interaction","score":0.5680000185966492}],"concepts":[{"id":"https://openalex.org/C2776701107","wikidata":"https://www.wikidata.org/wiki/Q416992","display_name":"Lurasidone","level":4,"score":0.767987847328186},{"id":"https://openalex.org/C44208683","wikidata":"https://www.wikidata.org/wiki/Q15335165","display_name":"Dopamine receptor D2","level":3,"score":0.6878026723861694},{"id":"https://openalex.org/C2780211496","wikidata":"https://www.wikidata.org/wiki/Q411188","display_name":"Aripiprazole","level":3,"score":0.6493839025497437},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.5874037146568298},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.5797283053398132},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.5313352346420288},{"id":"https://openalex.org/C2776921671","wikidata":"https://www.wikidata.org/wiki/Q758295","display_name":"Atypical antipsychotic","level":4,"score":0.4962382912635803},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.4651426374912262},{"id":"https://openalex.org/C58732023","wikidata":"https://www.wikidata.org/wiki/Q770260","display_name":"Partial agonist","level":4,"score":0.4518905282020569},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4307568669319153},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.4283524751663208},{"id":"https://openalex.org/C199596767","wikidata":"https://www.wikidata.org/wiki/Q21110872","display_name":"Dopamine receptor D3","level":4,"score":0.4179394841194153},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4141582250595093},{"id":"https://openalex.org/C137183658","wikidata":"https://www.wikidata.org/wiki/Q461076","display_name":"Dopaminergic","level":3,"score":0.41224613785743713},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.34962186217308044},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.2765393853187561},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.23143607378005981},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.2084914743900299}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2553714461","doi":null,"is_oa":false,"landing_page_url":"http://www.archivespp.pl/uploads/images/2010_12_4/NewmanTancredi5__archives%204_10.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":34,"referenced_works":["https://openalex.org/W95266284","https://openalex.org/W1497084816","https://openalex.org/W1564789152","https://openalex.org/W1597814345","https://openalex.org/W1845737189","https://openalex.org/W1968223004","https://openalex.org/W1971184880","https://openalex.org/W1986345142","https://openalex.org/W1986692070","https://openalex.org/W1986735308","https://openalex.org/W1990312367","https://openalex.org/W1991558370","https://openalex.org/W1994181466","https://openalex.org/W2003935114","https://openalex.org/W2007760893","https://openalex.org/W2021145153","https://openalex.org/W2023006010","https://openalex.org/W2026211985","https://openalex.org/W2027305485","https://openalex.org/W2029746418","https://openalex.org/W2036424845","https://openalex.org/W2053701494","https://openalex.org/W2070941417","https://openalex.org/W2071844775","https://openalex.org/W2092918233","https://openalex.org/W2096542244","https://openalex.org/W2107723089","https://openalex.org/W2122995608","https://openalex.org/W2142688346","https://openalex.org/W2153784874","https://openalex.org/W2166214376","https://openalex.org/W2166739899","https://openalex.org/W2167531441","https://openalex.org/W2460731912"],"related_works":["https://openalex.org/W2121361221","https://openalex.org/W1986484493","https://openalex.org/W3004056912","https://openalex.org/W2031298335","https://openalex.org/W1532804735","https://openalex.org/W2058784065","https://openalex.org/W1479919254","https://openalex.org/W1493995552","https://openalex.org/W95266284","https://openalex.org/W1497084816"],"abstract_inverted_index":{"Summary":[0],"Atypical":[1],"antipsychotics":[2],"are":[3],"antagonists":[4,43],"at":[5,80],"serotonin":[6],"5-HT2A":[7],"and":[8,18,23,36,70,104],"dopamine":[9],"d2":[10,116],"receptors.":[11],"However,":[12,92],"their":[13,97],"effects":[14],"on":[15,68],"negative":[16],"symptoms":[17],"cognitive":[19,72],"deficits":[20],"remain":[21],"modest":[22],"they":[24],"disrupt":[25],"metabolic":[26,87],"function.":[27],"Recent":[28],"drugs,":[29],"such":[30,85],"as":[31,39,86],"aripiprazole,":[32],"perospirone,":[33],"bifeprunox,":[34],"lurasidone":[35],"cariprazine":[37],"act":[38],"D2":[40],"recep-":[41],"tor":[42],"(or":[44],"partial":[45],"agonists)":[46],"combined":[47],"with":[48,83],"5-HT1A":[49,114],"receptor":[50,102],"activation.":[51],"The":[52],"latter":[53],"prevents":[54],"extrapy":[55],"-":[56],"ramidal":[57],"symptoms,":[58],"favors":[59],"prefrontal":[60],"cortex":[61],"dopaminergic":[62],"neurotransmission,":[63],"has":[64],"a":[65],"beneficial":[66],"influence":[67],"mood":[69],"opposes":[71],"deficits.":[73],"Further,":[74],"recent":[75],"drugs":[76,94],"exhibit":[77],"little":[78],"interaction":[79],"sites":[81],"associated":[82],"side-effects":[84],"disorders":[88],"or":[89],"autonomic":[90],"disturbance.":[91],"these":[93],"differ":[95],"in":[96],"bal-":[98],"ance":[99],"of":[100],"5-HT1A/D2":[101],"properties":[103],"this":[105],"is":[106],"likely":[107],"to":[108,110],"translate":[109],"distinct":[111],"therapeutic":[112],"profiles.":[113],"receptors/":[115,117],"antipsychotic/":[118],"schizophrenia":[119]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2553714461","counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":1}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-11-30T00:00:00"}
